Integrated Diagnostics HoldingsLSE:IDHC +0.81%58 ROE % is 51.67% as of Mar. 2026, which is 124% above its 10-year median of 23.10. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks better than 83.25% on this metric.
LSE:IDHC'
s ROE % Range Over the Past 10 Years
Min: 7.74 Med: 23.1 Max: 58.19
Current: 14.74
During the past 13 years, Integrated Diagnostics Holdings's highest ROE % was 58.19%. The lowest was 7.74%. And the median was 23.10%.
LSE:IDHC's ROE % is ranked better than 83.25% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.22
vs LSE:IDHC: 14.74
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Integrated Diagnostics Holdings ROE % Related Terms
Integrated Diagnostics Holdings ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Integrated Diagnostics Holdings (LSE:IDHC) has a ROE % of 51.67% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Integrated Diagnostics Holdings and its competitors. This is 124% above median its historical median of 23.10. Over the past decade, Integrated Diagnostics Holdings' ROE % has ranged from 7.74 to 58.19. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #34 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is Integrated Diagnostics Holdings' ROE % too high?
Integrated Diagnostics Holdings' current ROE % of 51.67% is 124% above median its 10-year median of 23.10. Over the past 10 years, this metric has ranged from a low of 7.74 to a high of 58.19. Based on the distribution chart, Integrated Diagnostics Holdings ranks #34 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #34 out of 203 companies for ROE %. This places Integrated Diagnostics Holdings in the top 17% of its industry — outperforming the majority of peers. Historically, Integrated Diagnostics Holdings' own ROE % has ranged from 7.74 to 58.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current ROE % is 51.67%, which is 124% above median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current ROE % is 51.67%, which is 124% above median its 10-year median of 23.10. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current ROE % is 51.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
ROE %: 51.67% (124% above median its 10-year median of 23.10)
GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
